clinical trial · NCT07500298
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
M.D. Anderson Cancer Center·phase1·not yet recruiting·n = 41
Phase 1SAR445877FOlfox6BevacizimabFirst Line TreatmentMetastatic Colorectal Cancer (CRC)Microsatellite StableSAR445877FOLFOX6Bevacizumab
brief summary
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
started
Sep 3, 2026
primary completion
Dec 27, 2030
completion
Dec 27, 2032
last updated
Mar 30, 2026
detailed description
Primary Objective •To determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of SAR445877 + FOLFOX6 and bevacizumab in patients with MSS metastatic CRC.
Secondary Objective
•To evaluate the antitumor efficacy of SAR445877 + FOLFOX6 and bevacizumab in participants with MSS metastatic CRC.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol